Want to see JP:4536 full AI Analyst Report?
Santen Pharmaceutical Co (4536) AI Stock Analysis
Santen Pharmaceutical Co
(TSE/TYO:4536)
The score is primarily supported by improved profitability and returns alongside a low-leverage balance sheet. Offsetting factors are softer cash-flow conversion and declining TTM free-cash-flow versus prior highs, while technical indicators point to weak near-term momentum despite some longer-term trend support. Valuation is reasonable with a modest dividend yield.
Santen Pharmaceutical Co (4536) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.53B
- Dividend Yield
- 2.24%
- Average Volume (3M)
- 1.23M
- Price to Earnings (P/E)
- 15.0
- Beta (1Y)
- 0.39
- Revenue Growth
- -0.72%
- EPS Growth
- 30.44%
- Country
- Japan
- Employees
- 3,968
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Santen Pharmaceutical Co Business Overview & Revenue Model
Company Description
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a vari...
How the Company Makes Money
Santen primarily makes money by selling ophthalmic prescription pharmaceuticals (and, where applicable, related eye-care products) to wholesalers, hospitals, clinics, and pharmacies, generating revenue when products are shipped and/or when control tr...
Santen Pharmaceutical Co Financial Statement Overview
Summary
Overall financials are healthy with a strong rebound in profitability and returns (TTM net margin ~12.8%, EBIT margin ~17.0%, ROE ~13.2%) and a conservative balance sheet (debt-to-equity ~0.12). The main offset is weaker cash conversion and negative TTM free-cash-flow growth versus prior periods, plus earnings volatility highlighted by a net loss in 2023.
Income Statement
78PositiveBalance Sheet
84Very PositiveCash Flow
66Positive| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 291.48B | 300.00B | 291.62B | 301.96B | 279.04B | 266.26B |
| Gross Profit | 156.58B | 163.21B | 160.97B | 163.88B | 156.57B | 146.85B |
| EBITDA | 62.21B | 66.51B | 67.79B | 48.88B | 11.94B | 52.92B |
| Net Income | 31.42B | 36.26B | 37.37B | 26.64B | -14.95B | 27.22B |
Balance Sheet | ||||||
| Total Assets | 389.14B | 409.28B | 423.03B | 435.70B | 421.18B | 459.98B |
| Cash, Cash Equivalents and Short-Term Investments | 63.56B | 93.00B | 80.88B | 94.58B | 57.90B | 83.01B |
| Total Debt | 35.63B | 33.95B | 34.75B | 35.16B | 35.96B | 22.00B |
| Total Liabilities | 115.53B | 124.10B | 127.02B | 130.33B | 127.88B | 123.13B |
| Stockholders Equity | 274.77B | 286.24B | 296.99B | 306.05B | 293.98B | 337.49B |
Cash Flow | ||||||
| Free Cash Flow | 38.82B | 54.27B | 36.66B | 63.33B | 19.87B | 28.70B |
| Operating Cash Flow | 46.19B | 60.93B | 43.50B | 72.65B | 37.15B | 46.04B |
| Investing Cash Flow | -13.32B | -8.22B | -12.97B | -6.14B | -26.78B | -35.17B |
| Financing Cash Flow | -57.04B | -53.31B | -49.35B | -34.03B | -37.22B | 5.56B |
Santen Pharmaceutical Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4536, the sentiment is Positive. The current price of 1789.50 is above the 20-day moving average (MA) of 1715.25, above the 50-day MA of 1754.59, and below the 200-day MA of 1793.83, indicating a neutral trend. The MACD of 7.58 indicates Negative momentum. The RSI at 62.43 is Neutral, neither overbought nor oversold. The STOCH value of 84.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4536.
Santen Pharmaceutical Co Peers Comparison
Overall Rating
JP:588973Outperform- JP:453669Neutral
JP:450364Neutral
JP:778062Neutral
JP:808641Neutral
JP:489038Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:5889 | 73Outperform | JPY 50.91B | 11.81 | ― | 4.06% | 15.36% | 5.16% |
| JP:4536 | 69Neutral | JPY 574.81B | 15.03 | 13.39% | 2.24% | -0.72% | 30.44% |
| JP:4503 | 64Neutral | JPY 4.63T | 12.62 | 20.41% | 3.07% | 16.93% | 347.13% |
| JP:7780 | 62Neutral | JPY 140.23B | 19.13 | 7.70% | 1.52% | 5.05% | 50.43% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:8086 | 41Neutral | JPY 240.39B | 15.81 | 5.35% | 2.27% | 2.68% | 144.20% |
| JP:4890 | 38Underperform | JPY 6.31B | -9.03 | ― | ― | -71.21% | -485.42% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4536 | Santen Pharmaceutical Co | 1789.50 | 314.88 | 21.35% | |
| JP:4503 | Astellas Pharma | 2571.00 | 1008.62 | 64.56% | |
| JP:7780 | Menicon Co | 1843.00 | 659.89 | 55.78% | |
| JP:8086 | Nipro Corporation | 1363.00 | -110.97 | -7.53% | |
| JP:4890 | Tsubota Laboratory Incorporated | 243.00 | -84.00 | -25.69% | |
| JP:5889 | Japan Eyewear Holdings Co.,Ltd. | 2093.00 | 158.55 | 8.20% |
Santen Pharmaceutical Co Corporate Events
Santen Completes Treasury Share Disposal for Performance-Linked Executive Stock Plan
Santen Pharmaceutical Co., Ltd., a long-established Japanese ophthalmic specialist, operates globally with a portfolio that spans key eye conditions including glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Its ex...
Santen to Dispose of Treasury Shares for Performance-Linked Executive Stock Plan
Santen Pharmaceutical will dispose of 68,912 treasury shares on September 30, 2026, at 1,867.5 yen per share, totaling about 128.7 million yen, to deliver stock-based remuneration under its Performance Share Unit plan for three directors and seven co...
Santen boosts profits in Q1 and maintains upbeat full-year outlook
Santen Pharmaceutical Co., Ltd. reported stable revenue of ¥68.96 billion for the three months ended June 30, 2026, a 0.3% increase year on year, while core operating profit rose 9.3% and net profit attributable to owners surged 22.4%. Earnings...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 09, 2026